Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limied

Kousuke Hidaka

Masato Yoshikawa

Naoki Ishii

Masashi Toyofuku

Masaki Daini

Hiroshi Nara

Akira Kaieda

Hideki Furukawa

Takeshi Yamasaki

Minoru Sasaki

Shizuo Kasai

Yoshito Terao

Takatoshi Yogo

Masashi Takahashi

Toshiki Murata

Ryoma Hara

Kyoko Toyofuku

The present invention aims to provide a heterocyclic compound having an IP6K inhibitory action and expected to be useful as a prophylactic or therapeutic agent for&#x2014;diseases such as cardiac failure, diabetes and the like. A compound represented by the formula (I): wherein each symbol is as defined in the SPECIFICATION, or a salt thereof has an IP6K inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for diseases such as cardiac failure, diabetes and the like. 

IP6K inhibitors

The present invention provide a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases, Charcot-Marie-Tooth disease and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Heterocyclic compound

The present invention provide a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases, Charcot-Marie-Tooth disease and the like, and a pharmaceutical composition comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Provided is an aromatic ring compound having a glucagon antagonistic action, which is useful for the prophylaxis or treatment of diabetes and the like. A compound represented by the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a salt thereof has a superior glucagon antagonistic action, and is useful as a glucagon antagonist, a glucose production inhibitor or an agent for the prophylaxis or treatment of diabetes and the like.

Aromatic ring compound

Growing community of inventors

Kanagawa, Japan

Kousuke Hidaka